Laza Medical, a Los Gatos, California company developing AI-powered robotic imaging for heart procedures, has raised up to $160m in a Series B round led by GE HealthCare. The company announced the financing on 4 November 2026.
Returning investors Unorthodox Ventures, PA MedTech and AMED also took part. Laza described the deal as structured financing of up to $160m, so the headline figure is a ceiling rather than a sum paid in at once. The company did not say how much is committed up front, how any later tranches are triggered, or what valuation the round set.
Law firm Sidley Austin said it advised Laza on the round, which it described as a Series B structured financing of up to $160m.
“The cath lab is poised for a fundamental evolution, and intelligent imaging powered by AI will play a defining role in what comes next.”Amr Salahieh, founder and board chairman, Laza Medical
What Laza Medical is building
Laza is building imaging systems for the cardiac catheterisation lab, the hospital room where doctors carry out procedures such as stent placements and structural heart repairs through catheters threaded into blood vessels. Its system pairs robotics with AI software to capture and guide images during these procedures.
The company says its goal is to simplify imaging in the cath lab, give clinicians more autonomy during procedures and lay the groundwork for robotic interventions in the future. RuntimeWire, which reported the round, said the aim is to make expert-level imaging more consistent from one procedure to the next.
The product is still in development. Laza's release states that the Laza Medical System is under development and is not approved for commercial sale in any geography. The company did not give a timeline for regulatory filings or clinical studies.
Who invested
GE HealthCare, one of the largest makers of medical imaging equipment, led the round. RuntimeWire reported that GE HealthCare had already invested in Laza's Series A and has now moved up to lead the Series B. The release did not set out any commercial agreement between the two companies alongside the investment.
Jyoti Gera, chief executive of cardiovascular and interventional solutions in GE HealthCare's advanced imaging business, said in the release: "The future of cardiac intervention must be one where access, consistency, and quality of care are no longer barriers to better outcomes." She said integrated imaging could redefine the cath lab and pave the way for robotic procedures.
Unorthodox Ventures, PA MedTech and AMED are all returning investors. The release did not give the size of each investor's commitment.
A Shifamed company
Laza is a privately held portfolio company of Shifamed, a medical device incubator in Los Gatos founded by Amr Salahieh, who is also Laza's founder and board chairman. Shifamed creates and backs separate companies around new device ideas, each with its own investors.
"The cath lab is poised for a fundamental evolution, and intelligent imaging powered by AI will play a defining role in what comes next," Salahieh said in the release. He added that the investors' support validated Laza's approach. Laza did not disclose its headcount, its founding year or the total it has raised to date.
The release said the money will support the company's plan to transform the cath lab through intelligent imaging, but it did not break down how the funds will be spent.
Company website: lazamedical.com